Rohto Pharmaceutical

4527.TPharmaceutical

Key numbers · FY ended 2026-03

Revenue¥343.7bn+11.4% YoY Operating income¥41.1bn+7.5% YoY Net income (owners)¥34.2bn+11.0% YoY Total assets¥485.8bn+11.2% YoY EPS (basic)¥151.56+12.0% YoY

Full financial history and reports →

Stock price4527 · View chart ↗

Open the price chart on TradingView.

Latest filings

Wed, Jan 7 · JST1 filing

16:05MATERIALRohto Pharmaceutical · Change in parent company or specified subsidiary

Wed, Feb 26 · JST1 filing

16:00MATERIALRohto Pharmaceutical · Securities issuance

All filings →

Major holders (5%+) · 0

Holder	Stake	Change	Filed

No holder currently reports 5% or more.

Each holder's own ratio from its most recent large-shareholding report.